Efficacy and safety of once‐weekly semaglutide vs once‐daily sitagliptin as add‐on to metformin in patients with type 2 diabetes ( SUSTAIN China): a 30‐week double‐blind, phase 3a, randomised trial
Published 2020 View Full Article
Published 2020 View Full Article
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now